Matthew Galsky, MD, on the CheckMate-274 study in high risk, muscle-invasive urothelial carcinoma
Dr. Galsky, Professor of Medicine, Director of Genitourinary Medical Oncology, Director of the Novel Therapeutics Unit, and Co-Director, Center of Excellence for Bladder Cancer, The Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, provides perspective on the outcomes of the CheckMate-274 study investigating nivolumab as adjuvant therapy for high risk, muscle-invasive urothelial carcinoma
